

## E. Coli Infections

[View the current E. Coli Infections InDepth page on BioPortfolio.com](http://www.bioportfolio.com/indepth/E._Coli_Infections.html) (PDF)

([http://www.bioportfolio.com/indepth/E.\\_Coli\\_Infections.html](http://www.bioportfolio.com/indepth/E._Coli_Infections.html)) - Regularly Updated.

### Recent Publications on E. Coli Infections:



- [A modified case-control study of cryptosporidiosis \(using non-Cryptosporidium-infected enteric cases as controls\) in a community setting.](#)  
*Data from the first sentinel site (Waterloo Region, Ontario) of the...*18th November, 2009  
Laboratory for Foodborne Zoonoses, Public Health Agency of Canada, Guelph,- *Epidemiol Infect.* 2009 Dec;137(12):1789-99. Epub 2009 Jun 16. ([DOI Direct Link](#))
- [Modelling the dynamics of intramammary E. coli infections in dairy cows: understanding mechanisms that distinguish transient from persistent infections.](#)  
*The majority of intramammary infections with Escherichia coli in dairy...*21st October, 2009  
- *Vet Res.* 2009 Oct 20;41(2):13. ([DOI Direct Link](#))
- [Antimicrobial use in the Australian pig industry: results of a national survey.](#)  
*OBJECTIVE: To describe how various antimicrobials are used in commercial...*16th October, 2009  
New South Wales Department of Primary Industries, Wollongbar, New South- *Aust Vet J.* 2009 Jun;87(6):222-9. ([DOI Direct Link](#))
- [Nitric oxide is an essential component of the hemocyte-mediated mosquito immune response against bacteria.](#)  
*Nitric oxide is a signaling and immune effector molecule synthesized by...*8th September, 2009  
Department of Biological Sciences and Institute for Global Health,- *Dev Comp Immunol.* 2009 Sep 11. ([DOI Direct Link](#))
- [Adaptation of Pathogenic E. coli to Various Niches: Genome Flexibility is the Key.](#)  
*It is a well-known observation and a long-standing hypothesis that...*22nd August, 2009  
Gottingen Genomics Laboratory, University of Gottingen, Gottingen,- *Genome Dyn.* 2009;6:110-125. Epub 2009 Aug 19. ([DOI Direct Link](#))
- [Different roles of host and bacterial factors in Escherichia coli extra-intestinal infections.](#)  
*Many host and bacterial factors contribute to the development of different...*24th June, 2009  
Division of Nephrology, College of Medicine, National Cheng Kung- *Clin Microbiol Infect.* 2009 Apr;15(4):372-9.
- [Enhancement of immunoprotective effect of CpG-ODN by formulation with polyphosphazenes against E. coli septicemia in neonatal chickens.](#)  
*Synthetic oligodeoxynucleotides (ODN) containing CpG motifs (CpG-ODN) have...*20th May, 2009  
Department of Veterinary Pathology, Western College of Veterinary- *Curr Drug Deliv.* 2009 Jan;6(1):76-82.
- [The influence of the mode of administration in the dissemination of three coliphages in chickens.](#)

- Escherichia coli* can cause severe respiratory and systemic infections in...16th May, 2009  
Research and Development Department, Controlvet, Seguranca Alimentar S.- Poult Sci. 2009  
Apr;88(4):728-33. ([DOI Direct Link](#))
- [Bacteriophages for prophylaxis and therapy in cattle, poultry and pigs.](#)  
*The successful use of virulent (lytic) bacteriophages (phages) in...*25th March, 2009  
Public Health Agency of Canada, Laboratory for Foodborne Zoonoses, Guelph,- Anim Health Res Rev.  
2008 Dec;9(2):201-15. ([DOI Direct Link](#))
  - [The antimicrobial protein psoriasin \(S100A7\) is upregulated in atopic dermatitis and after experimental skin barrier disruption.](#)  
*The innate defense of the skin against microbial threats is influenced by...*12th March, 2009  
Department of Dermatology, University Hospital of Schleswig-Holstein,- J Invest Dermatol. 2009  
Mar;129(3):641-9. Epub 2008 Aug 28. ([DOI Direct Link](#))
  - [The chicken as a natural model for extraintestinal infections caused by avian pathogenic Escherichia coli \(APEC\).](#)  
*E. coli* infections in avian species have become an economic threat to the...25th February, 2009  
Institute of Microbiology and Epizootics, Freie Universitat Berlin,- Microb Pathog. 2008  
Nov-Dec;45(5-6):361-9. Epub 2008 Sep 20. ([DOI Direct Link](#))
  - [Targeting virulence traits: potential strategies to combat extraintestinal pathogenic E. coli infections.](#)  
*Extraintestinal pathogenic Escherichia coli (ExPEC) are able to colonize,...*7th January, 2009  
University of Wurzburg, Institute for Molecular Infection Biology,- Curr Opin Microbiol. 2008  
Oct;11(5):409-13. Epub 2008 Oct 14. ([DOI Direct Link](#))
  - [Community-onset extended-spectrum beta-lactamase \(ESBL\) producing Escherichia coli: importance of international travel.](#)  
*OBJECTIVES: Extended-spectrum beta-lactamase (ESBL)-producing Escherichia...*6th January, 2009  
Department of Medicine, University of Calgary and Calgary Health Region,- J Infect. 2008  
Dec;57(6):441-8. Epub 2008 Nov 5. ([DOI Direct Link](#))
  - [The excretion of F18+ E. coli is reduced after oral immunisation of pigs with a FedF and F4 fimbriae conjugate.](#)  
*Currently, no vaccines are available for edema disease and post-weaning...*6th November, 2008  
Faculty of Veterinary Medicine, Ghent University, Salisburylaan 133, 9820- Vaccine. 2008 Apr  
16;26(17):2154-63.
  - [IL-15-induced CD8+CD122+ T cells increase antibacterial and anti-tumor immune responses: implications for immune function in aged mice.](#)  
*We previously proposed that mouse CD8(+)/CD122(+) T cells and human CD57(+)*...5th November, 2008  
Department of Immunology and Microbiology, National Defense Medical- J Leukoc Biol. 2008  
Oct;84(4):1047-56. Epub 2008 Jul 23. ([DOI Direct Link](#))

## BioNews Results for E. Coli Infections

- [Biotechnology Business: Study results from Microbiotix, Inc. broaden understanding of biotechnology business](#)  
*NewsRX: Nov 18 2009 2:14PM Matching: e coli infections*
- [Anacor Initiates Phase I Clinical Development for AN3365 A Novel Antibiotic for the Treatment of Gram-Negative Infections](#)  
*Business Wire UK: Nov 17 2009 12:23PM Matching: e coli infections*
- [Anacor Initiates Phase I Clinical Development for AN3365 -- A Novel Antibiotic for the Treatment of Gram-Negat](#)  
*RBC Dain Rauscher: Nov 17 2009 12:07PM Matching: e coli infections*

- [Anacor Initiates Phase I Clinical Development for AN3365 A Novel Antibiotic for the Treatment of Gram-Negative Infections](#)  
*Earthtimes.org: Nov 17 2009 12:34PM Matching: e coli infections*
- [Anacor Initiates Phase I Clinical Development for AN3365 A Novel Antibiotic for the Treatment of Gram-Negative Infections](#)  
*Earthtimes.org: Nov 17 2009 12:33PM Matching: e coli infections*
- [Anacor Initiates Phase I Clinical Development for AN3365 A Novel Antibiotic for the Treatment of Gram-Negative Infections](#)  
*Yahoo! Canada: Nov 17 2009 2:20PM Matching: e coli infections*
- [About 7 mn Healthcare-Associated Infections in the US, Europe annually](#)  
*Bio Spectrum Asia: Nov 12 2009 11:21AM Matching: e coli infections*
- [Recommendations for Diagnosis of Shiga Toxin-Producing Escherichia coli Infections by Clinical Laboratories](#)  
*Center for Disease Control and Prevention: Oct 15 2009 4:59PM Matching: e coli infections*
- [A multiplatform real-time polymerase chain reaction detection assay for Vibrio cholerae](#)  
*DiagnosticMicrobiology and Infectious Disease: Oct 12 2009 9:10PM Matching: e coli infections*

## E. Coli Infections Patents:



- 6809181- [Human beta-defensin-3 \(HBD-3\), a highly cationic beta-defensin antimicrobial peptide](#)
- 7094883- [Monoclonal antibody which agglutinates E. coli having the CS4-CFA/I family protein](#)
- 7115730- [Immunogenic detoxified mutant E. coli LT-A-toxin](#)
- 7132105- [Icosahedral superstructure of VP2 of infectious bursitis virus \(IBDV\) and the application thereof](#)
- 7183257- [Use of RPL41 to treat infections and inhibit cancer](#)
- 7193072- [Compositions to identify swine genetically resistant to F18 E. coli associated diseases](#)
- 7199128- [8-N-substituted-2H-isothiazolo\[5,4-b\]quinolizine-3,4-diones and related compounds as antiinfective agents](#)
- 7211426- [Isolated phages and their use in food or pet food products](#)
- 7214479- [E. coli O157:H7 C1-INH-binding protein and methods of use](#)
- 7252828- [Polysaccharide vaccine for staphylococcal infections](#)
- 7264922- [Method of reducing complement - mediated disruption of cells](#)
- 7094266- [Multipurpose, self-contained, portable and odor-free workstation](#)
- 7071293- [Alpha helical peptides with broad spectrum antimicrobial activity that are insensitive to salt](#)
- 7071232- [Small molecules that increase the conversion of food to body weight gain](#)
- 6824997- [Process and materials for the rapid detection of streptococcus pneumoniae employing purified antigen-specific antibodies](#)
- 6844010- [Therapeutic treatment and prevention of infections with a bioactive materials encapsulated within a biodegradable-biocompatible polymeric matrix](#)
- 6846485- [Fish serine proteinase and their pharmaceutical and cosmetic use](#)
- 6855814- [Sequences of E. coli O157](#)
- 6902743- [Therapeutic treatment and prevention of infections with a bioactive material\(s\) encapsulated within a biodegradable-bio-compatible polymeric matrix](#)
- 6965022- [Methods to identify swine genetically resistant to F18 E. coli associated diseases](#)

- 6967090- [Nucleic acid and protein sequences of bovine epidermal growth factor](#)
- 7001718- [Method of inhibiting pathogenicity of infectious agents](#)
- 7001744- [Recombinant DNA, plasmid, transformed microorganism and vaccine protein for prevention and therapy of urinary tract infection](#)
- 7015007- [Capsular polysaccharide adhesin antigen, preparation, purification and use](#)
- 7291588- [Immunogenic detoxified mutant E. coli LT-A toxin](#)
- 7297338- [Avian vaccine composition for the protection of poultry against disease and infection caused by E. coli and Salmonella](#)
- 7531507- [Acylated nonadepsipeptides containing pyridyl alanine residues](#)
- 7540049- [Support pillow for breastfeeding](#)
- 7544709- [Derivatives of andrimide and moiramide B having antibacterial properties](#)
- 7553805- [Methods and compositions for treating viral, fungal, and bacterial infections](#)
- 7566540- [Monoclonal antibody which agglutinates E. coli having the CS4-CFA/I family protein](#)
- 7588774- [Molecules enhancing dermal delivery of influenza vaccines](#)
- 7592159- [Antibiotic alternatives](#)
- 7604811- [Oral-intestinal vaccines against diseases caused by enteropathic organisms using antigens encapsulated within biodegradable-biocompatible microspheres](#)
- 7608291- [Treatment of infection in animals](#)
- 7612045- [Compounds, compositions and methods for controlling biofilms and bacterial infections](#)
- 7521060- [Pathogen for bacterial poultry disease](#)
- 7504251- [Bacterial strain, processed plant extracts, compositions containing same, processes for their preparation and their therapeutic and industrial applications](#)
- 7473247- [Intradermal delivery of vaccines and gene therapeutic agents via microcannula](#)
- 7348357- [Arylamides](#)
- 7351541- [Method for diagnosing a renal disorder](#)
- 7368424- [Acylated nonadepsipeptides](#)
- 7371393- [Methods for reducing fecal shedding](#)
- 7402683- [Cinnamic acid amides](#)
- 7404961- [Peptides responsive to antibodies against consensus peptide of the CS4-CFA/I family proteins](#)
- 7413743- [Active immunization using a siderophore receptor protein](#)
- 7446102- [Antibacterial amide macrocycles IV](#)
- 7459272- [Reduction in bacterial colonization by administering bacteriophage compositions](#)
- 7468258- [Self-quenching homofluorophore compositions for detecting enzyme activity](#)
- 7618640- [Method and composition for reducing E. coli disease and enhancing performance](#)

\*\*\*

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road,

